Capra Biosciences
Alexandria, US · Founded 2020 · Delaware corporation · 27 employees on LinkedIn · 6 known investors
Find your way into Capra Biosciences
Founders & leadership
Capra Biosciences was founded in 2020 by Andrew Magyar and Elizabeth Onderko.
Board
DJ
DC
Investors · 6
Reported raises · per SEC filings
Form D private placements$4M disclosed across 3 rounds · 2021–2024
▶$500KraisedOct 2024 · 1 investors · Other TechnologyRule 506(b)
▶$500KraisedOct 2024 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MagyarExecutive Officer, Director
- Elizabeth OnderkoExecutive Officer, Director, Promoter
- Pae WuDirector
- Douglas CameronDirector
- Danielle JosephDirector
- Offering amount
- $1.5M
- Amount sold
- $500K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3.4MraisedDec 2023 · 9 investors · Other TechnologyRule 506(b)
▶$3.4MraisedDec 2023 · 9 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Pae WuDirector
- Danielle JosephDirector
- Andrew MagyarExecutive Officer, Director, Promoter
- Douglas CameronDirector
- Elizabeth OnderkoExecutive Officer, Director, Promoter
- Offering amount
- $5M
- Amount sold
- $3.4M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$50KraisedJan 2022 · 1 investors · Other TechnologyRule 506(b)
▶$50KraisedJan 2022 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Elizabeth OnderkoExecutive Officer, Director, Promoter
- Andrew MagyarExecutive Officer, Director, Promoter
- Offering amount
- $1.5M
- Amount sold
- $50K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Cambrian Bio4 shared keywordsCambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR. Its lead asset, ATX-304, is an AMPK Network Activator being developed for obesity and prediabetes.
Capricor4 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Bicara Therapeutics4 shared keywordsBicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors. The company's lead program, ficerafusp alfa, fuses an EGFR-directed antibody with a TGF-β ligand trap to simultaneously inhibit tumor cell growth and suppress immunosuppressive signaling in the tumor microenvironment, with initial development focused on head and neck squamous cell carcinoma.
Pacira NASDAQ: PCRX www.pacira.com3 shared keywordsPacira develops and commercializes non-opioid therapies for postsurgical, chronic, and musculoskeletal pain, and is advancing a gene therapy pipeline candidate. It serves patients and healthcare providers seeking alternatives to opioid pain management.
BIOVECTRA3 shared keywordsBIOVECTRA is a contract development and manufacturing organization (CDMO) with research and development capabilities in biologics process development, complex chemistry, and analytical development. Its work spans recombinant proteins, viral vectors, mRNA vaccines, and pharmaceutical process development for the biotech and pharmaceutical industries.
Fortis Life Sciences3 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Bridgebio3 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Privco3 shared keywordsPrivCo provides sales teams with company intelligence and prospect targeting tools, including verified contact data for decision makers, financial information, and competitive insights to support targeted outreach and qualification.
Companies competing with Capra Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
BioHealth Capital Region - Regional Life Sciences Roundup - August 7, 2026 | BioBuzzbiobuzz.io · Aug 2026Frequently asked questions
- Who founded Capra Biosciences?
- Capra Biosciences was founded by Andrew Magyar, Elizabeth Onderko in 2020.
- Who are Capra Biosciences's investors?
- Capra Biosciences's investors include Blue Ivy Ventures, First Bight Ventures, GS Futures, Closed Loop Partners, SOSV, The E14 Fund.
- How much funding has Capra Biosciences raised?
- Capra Biosciences has disclosed $4M raised across 3 rounds.
- Where is Capra Biosciences headquartered?
- Capra Biosciences is headquartered in Alexandria, US.